HER2 expression as a potential marker for response to therapy targeted to the EGFR
作者： D R Emlet , R Schwartz , K A Brown , A A Pollice , C A Smith
关键词:
摘要: Since human epidermal growth factor receptor 2 (HER2) is known to participate with the (EGFR) in mitogenic signalling, we hypothesised that HER2 overexpression might indicate responsiveness EGFR targeted therapies. MCF7 breast cancer cells transfected gene were subcloned establish a set of genetically related cell lines expressing graded levels by immunoblot analysis. The and parental characterised their characteristics, patterns EGFR, HER3 expression as well phosphorylated mitogen-activated protein kinase (MAPK) AKT laser scanning cytometry (LSC). Growth inhibition assays used characterise response therapy, determine relationship between therapeutic tyrosine expression. AG1478 AG1478-trastuzumab combinations correlated among different lines. Among HER3, was best single predictive marker, but two markers provided additional information.
nature.com
sci-hub.se 参考文章(49)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
John D Minna, Adi F Gazdar, Stephen R Sprang, Joachim Herz, A Bull's Eye for Targeted Lung Cancer Therapy Science. ,vol. 304, pp. 1458- 1461 ,(2004) , 10.1126/SCIENCE.1099578
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
J Baselga, Clinical trials of Herceptin® (trastuzumab) European Journal of Cancer. ,vol. 37, pp. 18- 24 ,(2001) , 10.1016/S0959-8049(00)00404-4
Romàn Pérez-Soler, Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer Clinical Lung Cancer. ,vol. 6, pp. S20- S23 ,(2004) , 10.3816/CLC.2004.S.010
Carlos L Arteaga, Cristina I Truica, Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer Seminars in Oncology. ,vol. 31, pp. 3- 8 ,(2004) , 10.1053/J.SEMINONCOL.2004.01.006
Zhenhe Suo, Bj�rn Risberg, Mats G. Kalsson, Kenneth Willman, Anne Tierens, Eva Skovlund, Jahn M. Nesland, EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival The Journal of Pathology. ,vol. 196, pp. 17- 25 ,(2002) , 10.1002/PATH.1003
Agnese A. Pollice, J. Philip Mccoy, Stanley E. Shackney, Charles A. Smith, Jyotsna Agarwal, Dennis R. Burnolt, Laura E. Janocko, Francis J. Hornicek, Sarita G. Singh, Robert J. Hartsock, Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry. ,vol. 13, pp. 432- 444 ,(1992) , 10.1002/CYTO.990130414
Yosef Yarden, Biology of HER2 and Its Importance in Breast Cancer Oncology. ,vol. 61, pp. 1- 13 ,(2001) , 10.1159/000055396